Brief: Protagenic Therapeutics Approves Restructuring Plan on August 8- SEC Filing

Protagenic Therapeutics

13/08/2025 22:57

Aug 13 (Reuters) - Protagenic Therapeutics Inc PTIX.O:

PROTAGENIC THERAPEUTICS INC - ON AUGUST 8 APPROVES FOCUSED RESTRUCTURING PLAN - SEC FILING

PROTAGENIC THERAPEUTICS INC: RESTRUCTURING PLAN TO TRANSITION TO VIRTUAL OPERATING MODEL, CONCENTRATE CAPITAL ON  HIGHEST-PRIORITY CLINICAL PROGRAM(S)

PROTAGENIC THERAPEUTICS INC: HAS TEMPORARILY SUSPENDED EXPENDITURES RELATED TO PRECLINICAL PROGRAMS

PROTAGENIC THERAPEUTICS INC: INITIATED PROCESS TO EVALUATE STRATEGIC ALTERNATIVES FOR THOSE PROGRAMS, INCLUDING PARTNERSHIPS AND/OR OUT-LICENSING

PROTAGENIC THERAPEUTICS INC: REDUCING OPERATING EXPENSES, OVERHEAD, AND HEADCOUNT PRIMARILY ASSOCIATED WITH PRECLINICAL ACTIVITIES

PROTAGENIC THERAPEUTICS : WHEN FULLY IMPLEMENTED, RESTRUCTURING PLAN IS EXPECTED TO REDUCE ANNUALIZED OPERATING EXPENSES BY ABOUT $8 MILLION

PROTAGENIC THERAPEUTICS : TERMINATED EMPLOYMENT OF BARRETT EVANS AS CEO AND PRESIDENT AND COLIN STOTT AS CHIEF OPERATING OFFICER

PROTAGENIC THERAPEUTICS INC: APPROVED A CHANGE IN CO'S FISCAL YEAR-END FROM DECEMBER 31 TO MARCH 31, EFFECTIVE IMMEDIATELY

PROTAGENIC THERAPEUTICS:ALL PRECLINICAL PROGRAMS ORIGINATED WITH FORMER PHYTANIX BIO (PHYX-001,PHYX-002,PHYX-003,PHYX-004, PHYX-005) HAVE BEEN PAUSED

Source text: [ID:n0001641172-25-023588]

Further company coverage: PTIX.O

 ((Reuters.Briefs@thomsonreuters.com;))